The FDA granted accelerated approval to Ipsen Pharma’s Iqirvo 80 mg, a first-in-class oral, once-daily peroxisome proliferator-activated receptor agonist for the treatment of primary biliary cholangitis, according to a company release.
Originally given breakthrough therapy designation in 2019, Iqirvo (elafibranor, Ipsen/Genfit), is now indicated as second-line therapy in combination with
FDA rejects expanded use of Dynavax's four-dose hepatitis B vaccine for hemodialysis healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
FDA approves ColoSense stool RNA test to detect colorectal cancer in average-risk adults healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
King Street shock as car ploughs through Midas shop window warringtonguardian.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from warringtonguardian.co.uk Daily Mail and Mail on Sunday newspapers.